top of page
February 3, 2026 Adecto Pharmaceuticals announces patent issuance for licensed cancer therapy and diagnostic technology
July 22, 2024 Adecto Pharmaceuticals announces exclusive licensing agreement with Tufts University to develop ADAM8-targeted monoclonal antibodies for treatment of aggressive cancers
March 1, 2023 Adecto Pharmaceuticals names co-founder Dr. Nora Mineva as Chief Executive Officer
September 1, 2022 Adecto Pharmaceuticals awarded Phase II NCI SBIR grant to continue development of an ADAM8 cancer diagnostic
August 11, 2020 Adecto Pharmaceuticals president Dr. Gail Sonenshein receives Tufts University School of Medicine 2020 Zucker Award for outstanding career achievements in women's health research
May 24, 2019 Adecto Pharmaceuticals awarded Phase I NCI SBIR grant for development of ADAM8 cancer diagnostic
October 22, 2018 Adecto Pharmaceuticals awarded multimillion-dollar NCI SBIR grant to continue development of ADAM8 targeted therapy
March 1, 2018 Adecto Pharmaceuticals selected to participate in MassBio’s MassCONNECT mentoring program
April 2, 2017 Adecto Pharmaceuticals presents poster on selection of lead candidate therapeutic antibodies at the 2017 AACR annual meeting
April 15, 2016 Adecto Pharmaceuticals awarded Phase I NCI STTR grant for the development of ADAM8 targeted therapies
April 13, 2015 Adecto Pharmaceuticals wins Tufts $100K New Ventures Competition
March 18, 2014 New Hope for Tough-to-Treat Breast Cancers Tufts researchers find promising target in battle against aggressive tumors
bottom of page
